Enfamil Neuropro Gentlease Market Report: Sales Volume, Market Share, Leading Brands & Market Trends

Similac is the best-performing enfamil neuropro gentlease brand in July 2026, moving 17,000 units across 4 ASINs for 39.5% of Top 10 volume. Bubs follows with 13,000 units (30.2%), ahead of Enfamil on 6,000 units (14.0%).

With 5 brands splitting the Top 10 and 83.7% of volume sitting with three of them, this is a concentrated shelf — the leaders hold multiple listings or one very high-velocity ASIN, so a new entrant competes against established review moats rather than an open field. Average selling prices among the leaders run from $30.19 to $115.85, which frames the price band a competing listing has to justify.

Based on July 2026 data, this shortlist surfaces the two kinds of ASIN worth keeping an eye on — the ones that just broke into the Top 10, and the ones growing fastest month over month. Specifically, 2 ASINs forced its way in: B006609HYI booked 3K units at $70.08, with ▲ 50.0% MoM change. On the growth side, B00L99TS2M leads positive momentum with ▲ 100.0% MoM growth on 2K units.

The two signals carry different weight. A fresh entrant means share has already changed hands — an incumbent gave up its place to make room, so any competitive set drawn up a month ago is now out of date. A steep growth rate works as the earlier warning: it marks demand that is still compounding, usually a month or two before the ranking catches up to it.